Journal article
Comparison of Pretreatment Strategies for cT2cN0 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A European High-Volume Center Cohort Analysis
Abstract
BackgroundAfter the ESOPEC trial showed a survival benefit for fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)-treated adenocarcinomas of the esophagus (EAC) and the gastroesophageal junction (GEJ) compared with Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS), a European, high-volume center study for stage cT2cN0 EAC and GEJ was undertaken, as it has been published that a third of these patients are …
Authors
Wirsik NM; Schmidt T; Kooij CD; Dempster N; Crnovrsanin N; Donlon NE; Uzun E; Bhanot K; Nienhüser H; Polette D
Journal
Annals of Surgical Oncology, Vol. 32, No. 13, pp. 10128–10136
Publisher
Springer Nature
Publication Date
12 2025
DOI
10.1245/s10434-025-18311-8
ISSN
1068-9265
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
HumansMaleEsophagogastric JunctionEsophageal NeoplasmsFemaleAdenocarcinomaAgedRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsSurvival RateMiddle AgedNeoplasm StagingHospitals, High-VolumeFollow-Up StudiesPrognosisDocetaxelOxaliplatinEsophagectomyLeucovorinFluorouracilEuropeChemoradiotherapyCombined Modality TherapyGastrectomy